[16] Beck J D, Reidenbach D, Salomon N, et al. mRNA therapeutics in cancer immunotherapy[J/OL]. Mol Cancer, 2021, 20(1): 69[202203-01]. https://molecular-cancer.biomedcentral.com/articles/10.1186/ s12943-021-01348-0. DOI: 10.1...
Beck, J.D., Reidenbach, D., Salomon, N. et al. mRNA therapeutics in cancer immunotherapy. Mol Cancer 20, 69 (2021). Diken, M.; Kranz, L.M.; Kreiter, S.; Sahin, U. mRNA: A Versatile Molecule for Cancer Vaccines...
1. Jan D. Beck et al. mRNA therapeutics in cancer immunotherapy. Molecular Cancer. 2021. 20: 69.2. Stadler, C.R. et al. Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nat Med. 2017. 23, 815-817.3. 于晴, 黄婷婷, 邓子新. 微生物药物产业现状与发展趋势. 中...
mRNA therapeutics have become the focus of molecular medicine research. Various mRNA applications have reached major milestones at high speed in the immuno-oncology field. This can be attributed to the knowledge that mRNA is one of nature’s core buildin
Jan D. Beck et al,mRNA therapeutics in cancer immunotherapy, Molecular Cancer (2021) 20:69 (本文由BioNTech攥写) Van Hoecke et al. mRNA in cancer immunotherapy: beyond a source of antigen,Molecular Cancer (2021) 20:48
mRNA-Based Therapeutics in Cancer Treatment.Pharmaceutics.2023Feb13;15(2):622.doi:10.3390/pharmaceutics15020622.PMID:36839944;PMCID:PMC9964383. [2]Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, CegliaN, Guasp P, Chu A, Yu R, Chandra AK, Waters T, Ruan J, ...
[1]Sun H, Zhang Y, Wang G, Yang W, Xu Y. mRNA-Based Therapeutics in Cancer Treatment.Pharmaceutics.2023Feb13;15(2):622.doi:10.3390/pharmaceutics15020622.PMID:36839944;PMCID:PMC9964383. [2]Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, CegliaN, Guasp P, ...
Pfizer-BioNTech和Moderna Therapeutics于2020年开发了两个基于mRNA技术的新型疫苗平台(分别是comirnaty®和spikevax®),并且是第一个功效高于90%的疫苗平台。两者均由编码SARS-COVID-19 Spike蛋白的N1-甲基-假尿苷修饰的mRNA组成,并采用脂质纳米颗粒(LNP)制剂递送。
[1]Sun H, Zhang Y, Wang G, Yang W, Xu Y. mRNA-Based Therapeutics in Cancer Treatment.Pharmaceutics.2023Feb13;15(2):622.doi:10.3390/pharmaceutics15020622.PMID:36839944;PMCID:PMC9964383. [2]Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, CegliaN, Guasp P, ...
Pfizer-BioNTech和Moderna Therapeutics于2020年开发了两个基于mRNA技术的新型疫苗平台(分别是comirnaty®和spikevax®),并且是第一个功效高于90%的疫苗平台。两者均由编码SARS-COVID-19 Spike蛋白的N1-甲基-假尿苷修饰的mRNA组成,并采用脂质纳米颗粒(LNP)制剂递送。